Factor Model (net +1.5)
Factor Model
net +1.5 3.9 / 10Q2 beat and raised FY26 guidance on MFA integration
Watch: Monitor FY26 net income realization against the raised guidance—margin expansion from pricing resets is key to justifying the upward revision. Watch for any slowdown in segment growth rates in H2 as pricing leverage saturates.
Phibro Animal Health delivered a strong Q2 with 21% revenue growth to $94M and 60% adjusted net income growth, prompting management to raise full-year guidance across revenue, EBITDA, and adjusted net income. The Zoetis MFA portfolio integration—a key acquisition driver—is largely complete, with pricing resets now flowing through to improved margins. Vaccines grew 13% and nutritional specialties grew 9% in the quarter.
The combination of organic momentum and margin accretion from the MFA integration demonstrates the acquisition thesis is working. Raising guidance mid-cycle signals management confidence in sustained momentum, not a one-quarter pop.
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when PAHC changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.